As a follow-up to this finding, we assessed the significantly increased expressions of TIGIT+CD226− and TIGIT+Foxp3+ γδ T-cell subsets in de novo patients with AML, which indicated the exhaustion and heterogeneity of T cells (30). This evidence concerns the gene FOXP3 and acute myeloid leukemia.